Dark Genome Biotech HERVolution Therapeutics Announces $11.7M Series A to Advance Treatments for Cancer & Diseases of Aging
The company engineers novel immunotherapies that empower the immune system to target HERV antigens from the dark genome to treat cancer, metabolic disease, and other aging-related diseases Funds to fuel pipeline of off-the-shelf assets through…